Last reviewed · How we verify
hUCB
hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery.
hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery. Used for Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant, Bone marrow failure syndromes, Severe aplastic anemia.
At a glance
| Generic name | hUCB |
|---|---|
| Sponsor | StemCyte Taiwan Co., Ltd. |
| Drug class | Allogeneic hematopoietic stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology / Hematology |
| Phase | FDA-approved |
Mechanism of action
hUCB (human umbilical cord blood) contains hematopoietic stem cells and progenitor cells that can differentiate into various blood cell lineages. When infused, these cells engraft in the bone marrow and restore hematopoietic function, red blood cell production, platelet production, and immune cell populations. The therapy is used primarily as an allogeneic stem cell source for transplantation in patients with hematologic malignancies or bone marrow failure syndromes.
Approved indications
- Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant
- Bone marrow failure syndromes
- Severe aplastic anemia
Common side effects
- Graft-versus-host disease (GVHD)
- Infection
- Engraftment failure or delayed engraftment
- Cytopenias
Key clinical trials
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke (PHASE1)
- Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS) (PHASE2)
- Human Umbilical Cord Blood Infusion in Patients with Cerebral Palsy (PHASE1)
- PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants (PHASE2)
- Stem Cells for Bronchopulmonary Dysplasia (EARLY_PHASE1)
- Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial. (PHASE1, PHASE2)
- Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hUCB CI brief — competitive landscape report
- hUCB updates RSS · CI watch RSS
- StemCyte Taiwan Co., Ltd. portfolio CI